Creating new proteins to enhance T-cell therapies for cancer and other diseases
Engineering Protein Modulators of Notch Activation for T-cell immunotherapy
This study is working on new ways to boost a process that helps turn stem cells into T-cells, which are important for fighting diseases like cancer and autoimmune disorders, so that patients can have better and easier access to T-cell therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10896918 on NIH RePORTER |
What this research studies
This research focuses on developing innovative protein activators that enhance the Notch signaling pathway, which is crucial for T-cell differentiation from stem cells. By engineering these proteins, the research aims to simplify and improve the process of creating T-cell therapies for various conditions, including cancer and autoimmune diseases. The approach involves using specialized nanobodies to activate Notch receptors without the need for complex co-culture systems, making the therapy development more efficient. Patients may benefit from more effective and accessible T-cell therapies as a result of this work.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancer, autoimmune disorders, or those requiring T-cell therapies.
Not a fit: Patients with conditions unrelated to T-cell therapies or those who do not require immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective T-cell therapies for cancer and other serious diseases.
How similar studies have performed: Previous research has shown promise in enhancing T-cell therapies through innovative engineering approaches, indicating potential for success in this novel method.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Muretta, Joseph M. — University of Minnesota
- Study coordinator: Muretta, Joseph M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.